Risk and Volatility Acutus Medical has a beta of -1.28, meaning that its stock price is 228% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Profitability This table compares Acutus Medical and T2 Biosystems' net margins,
T2 Biosystems, Inc. (NASDAQ: TTOO - Get Free Report) passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.02 and traded as low as $0.0020. T2 Biosystems shares last traded at $0.0020, with a volume of 9,130 shares changing hands. T2 Biosystems
Valuation and Earnings This table compares Minerva Surgical and T2 Biosystems"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Surgical $51.69 million 0.00 -$34.11 million ($8.21) 0.00 T2 Biosystems $7.68 million 0.01 -$50.08 million ($3.89) 0.00 Minerva Surgical has higher revenue and earnings than
Shares of T2 Biosystems, Inc. (NASDAQ: TTOO - Get Free Report) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $0.01 and traded as high as $0.0115. T2 Biosystems shares last traded at $0.0110, with a volume of 34,136 shares trading hands. T2 Biosystems
T2 Biosystems, Inc. (NASDAQ: TTOO - Get Free Report)'s share price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.01 and traded as high as $0.0131. T2 Biosystems shares last traded at $0.0110, with a volume of 10,180 shares changing hands. T2 Biosystems
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream
T2 Biosystems, Inc. (NASDAQ:TTOO ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Operator Greetings.
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024.
T2 Biosystems, Inc. (NASDAQ:TTOO ) Business Update Conference Call October 10, 2024 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman and CEO Conference Call Participants Eduardo Martinez - H.C. Wainwright Operator Good day, everyone.
